FDA and state rules, for what you actually buy.

Must a pharmacy located in another state hold a license/registration from this state to ship prescriptions (including patient-specific 503A compounded preparations) to patients or practitioners here?

24 Del. C. §2535(a) requires a pharmacy in another state, DC or a U.S. territory that delivers, dispenses or distributes a prescription drug to an ultimate user in Delaware to obtain a nonresident pharmacy license, and bars delivery without one. To be licensed, the pharmacy must hold licenses in good standing everywhere it is licensed, have no discipline, and submit its most recent Board-approved inspection report covering all aspects of the business used in Delaware, performed by or for the home-state regulator; if no qualifying home-state inspection exists, a report from NABP's Verified Pharmacy Program or another Board-approved entity is required. Shipped (not hand-delivered) prescriptions must carry a written notice about temperature effects and a local or toll-free line staffed by a registered pharmacist. A nonresident pharmacy must designate a Delaware registered agent (§2536), and operating without a license can bring a fine of up to $10,000 per day (§2538(b)). No separate nonresident sterile-compounding permit or Delaware-licensed PIC requirement appears in the statute.

§2535 was most recently amended by 85 Del. Laws c. 49; that act also repealed the old permit-fee sections effective June 30, 2026, so Delaware's pharmacy chapter was restructured in 2025–2026. Delaware Board of Pharmacy (Division of Professional Regulation) administers licensing.

May a 503A (traditional) pharmacy dispense or distribute compounded preparations to a practitioner for office use (administration in the office, not patient-specific)? The federal position is that 503A requires patient-specific prescriptions; this is what the state pharmacy act and board rules allow.

24 Del. C. §2502 defines compounding as preparing a drug as the result of a practitioner's prescription or initiative (including anticipatory compounding based on routine, regularly observed prescribing patterns) and says nothing in the title limits a prescriber's ability under pre-existing law to order a compounded medication for use in the prescriber's practice 'as permitted by State of Delaware and federal law.' The Board's compounding rule (24 Del. Admin. Code 2500-10.0) only requires compliance with USP <795>, <797> and <800> and contains no office-use quantity, labeling or record limits. Because the statute defers to federal law, and FDA's position is that 503A compounding requires patient-specific prescriptions, Delaware law does not by itself confirm that a 503A pharmacy may supply office stock. The Delaware Board of Pharmacy enforces.

Marked unknown because Delaware's text is a savings clause, not an authorization: it neither sets office-use limits nor prohibits office use, and points back to federal law. Nothing addresses nonresident pharmacies shipping office stock. Compounding rule last amended 2018 (possibly stale). Check with the Delaware Board of Pharmacy: https://dpr.delaware.gov/boards/pharmacy/

Does the state require an FDA-registered 503B outsourcing facility located outside the state to hold a state license/registration (as an outsourcing facility, nonresident manufacturer, wholesaler or pharmacy) before shipping into the state?

24 Del. C. §2502(26) defines an outsourcing facility as an FDA-registered 503B facility in the U.S. 'doing business within or into Delaware' that is licensed with the Board as a wholesaler before applying, and is licensed with the Board as an outsourcing facility. Under §2540A(c) the applicant must supply ownership and key-personnel information (designated representative and supervisor), a recent GMP inspection report acceptable to the Board, and proof of home-state licensure or registration where applicable; §2540A(a) adds fingerprint-based criminal background checks for key personnel and a separate license for each location. Board rule 24 Del. Admin. Code 2500-8.0 says wholesalers, manufacturers, outsourcing facilities and third-party logistics providers that operate within Delaware, 'whether or not physically located within this state,' must first obtain a Board permit, designate a Delaware registered agent, and follow Delaware law as well as home-state law; it also provides for Board inspection before initial licensure.

§2540A was added by 85 Del. Laws c. 49 (2025–2026 restructuring of the Pharmacy Act). The Board rule 2500-8.0 predates that act (last amended 2018) and may be revised. If the 503B also dispenses patient-specific prescriptions to Delaware patients, the nonresident pharmacy license (§2535) is a separate requirement.

Has the state signed FDA's standard Memorandum of Understanding Addressing Certain Distributions of Compounded Human Drug Products (October 2020)? If not, FD&C Act §503A limits its 503A pharmacies' out-of-state distribution to 5% of total prescription orders (currently not enforced by FDA pending rulemaking).

Signing the standard MOU means the state board agrees to investigate complaints about compounded drugs its 503A pharmacies ship out of state and to identify and report to FDA pharmacies that distribute "inordinate amounts" interstate (more than 50% of their compounded prescriptions); in exchange, the statutory 5% out-of-state cap in FD&C Act §503A(b)(3)(B) does not apply to that state's pharmacies. FDA lists only Colorado, Kentucky and New Hampshire as signatories; Delaware is not among them. For a non-signing state, FD&C Act §503A(b)(3)(B)(ii) caps a 503A pharmacy's out-of-state distribution of compounded drugs at 5% of its total prescription orders. FDA now considers the October 2020 standard MOU suspended (it does not expect signatory states to carry out MOU activities and will not sign new ones) and is not enforcing the 5% limit until a final rule and an updated MOU are published; FDA's rulemaking (RIN 0910-AI71) listed a proposed rule for 11/2026 in the Fall 2025 Unified Agenda.

The FDA list of signed MOUs (current as of 2023-01-23) is older than 2 years, but FDA stopped entering new agreements under the 2020 MOU in October 2022, so no state can have signed since. The FDA "Compounding Information for States" page (current as of 2026-08-28) still describes the MOU as awaiting rulemaking. Pending: FDA proposed rule on 503A distribution (RIN 0910-AI71, NPRM projected 11/2026); H.R. 5316 (introduced 2025-09-11, referred to House Energy & Commerce) would remove the MOU provision from §503A.

Besides DEA registration, does the state require practitioners to hold a separate state controlled substance registration, license or permit to prescribe, administer or dispense controlled substances (e.g. testosterone, Schedule III)? "Conditional" means a state registration is needed only in some settings, such as keeping controlled-substance stock in the office.

16 Del. C. Sec. 4732(a) requires any practitioner - including one holding a practice privilege, compact license, interstate telehealth registration or military registration - who engages in controlled-substance activities in Delaware to obtain biennially a registration issued by the Secretary of State. The Division of Professional Regulation's Office of Controlled Substances issues the CSR; the physician CSR application fee is $210, renewal fees are set at renewal, and registrations expire June 30 of odd-numbered years. The Division states that after the Delaware CSR is approved the practitioner files for a Delaware DEA registration, and both are needed before prescribing. A separate CSR is required for each additional location where controlled substances are dispensed or stored for patient administration. APRNs, PAs and optometrists apply through their own CSR pages.

Telehealth-relevant: the statute expressly covers practitioners holding an interstate telehealth registration. Per-location: separate CSR for each extra site that stores/dispenses controlled substances.

Must a prescriber query the state Prescription Drug Monitoring Program before prescribing, and does the mandate cover Schedule III drugs such as testosterone? "Yes" means a mandate that reaches Schedule III; "conditional" means a mandate limited to certain drugs (e.g. opioids or benzodiazepines) or situations; "no" means no prescriber query mandate.

16 Del. C. 4798(f) requires a prescriber to obtain a 12-month PMP report before prescribing any Schedule II-V controlled substance only when the prescriber has a reasonable belief the patient may be seeking it for reasons other than treating an existing medical condition. The Uniform Controlled Substances Act Regulations, section 9.0 (safe prescribing of opioid analgesics), require a PMP query when a first acute-pain opioid prescription exceeds 7 days, before the first subsequent opioid prescription beyond the initial 7 days, and for chronic pain patients at least every six months (or whenever a benzodiazepine is also prescribed). Section 9.0 exempts hospice, active cancer/cancer pain, terminally ill/palliative patients and hospital patients (discharge supplies of 7 days or less). Administered by the Office of Controlled Substances in the Division of Professional Regulation.

Source older than 2 years - possibly stale (Regulation 9.0 last amended 25 DE Reg. 873, 3/1/2022). Testosterone (C-III) is caught only under the statutory 'reasonable belief' of misuse trigger. Pharmacists have a parallel reasonable-belief duty (4798(e)). PDMP TTAC also cites CDR 24-0001 §§ 9.5, 9.6, 9.8; board-specific rules (e.g., Board of Medical Licensure Reg. 1700) were not reviewed. The official Delaware regulations site is script-rendered and could not be read directly.

May physicians dispense prescription drugs (not just administer them) directly to patients from their practice? "Yes" means allowed under standard rules (labeling, records, and at most a simple notice to the board); "conditional" means a separate dispensing registration, permit or license, or quantity, day-supply or drug-category limits; "no" means prohibited except narrow exceptions.

24 Del. C. 2523(4) says nothing in the pharmacy chapter prevents a practitioner licensed in Delaware from practicing within the scope of that license. Under 24 Del. C. 2522(c), practitioners who sell or dispense drugs directly to patients must label the drugs or give a document with patient name and address, date, practitioner name, phone and address, the DEA number for controlled substances, drug name, strength, form and quantity, refills and directions. No separate dispensing permit was found; controlled substances require Delaware and DEA registration.

Some compilations label Delaware's pharmacy chapter 'effective until June 30, 2026', suggesting a 2026 rewrite; text above is the version on delcode.delaware.gov at access. Check the current chapter.

For a patient located in the state: must the prescriber hold this state's license (or a telehealth registration or special license), is an in-person exam required before prescribing (generally or for controlled substances), are there state limits on prescribing Schedule III drugs such as testosterone by telehealth, and is the state an Interstate Medical Licensure Compact member? "Yes" means a state license and the in-person standard of care apply (opioid-only or Schedule II-only limits are described but do not change the answer); "conditional" means extra state conditions such as a telehealth registration route, an in-person exam requirement, controlled-substance limits reaching Schedule III, or registration of telehealth businesses. Federal DEA rules apply on top.

A provider licensed in a state that has not adopted an applicable interstate compact may practice telehealth in Delaware only with an interstate telehealth registration from the Division of Professional Regulation (24 Del. C. 6002), which subjects the provider to Delaware law. A provider-patient relationship may be established in person or by telehealth if it includes identity and location verification, a diagnosis through acceptable practices (history, exam as warranted, testing) and the same standard of care as in person (24 Del. C. 6003, 6005). No Delaware telehealth-specific Schedule III limit was found. IMLC: member.

Delaware Board of Medical Licensure and Discipline administers Medical Interstate Telehealth Registrations. Delaware's controlled substance registration (16 Del. C. 4732) expressly covers practitioners working under an interstate telehealth registration (see the state_csr topic).

Who may administer botulinum toxin and dermal fillers (physicians, PAs, NPs, RNs, LPNs, estheticians, dentists), under what supervision (on-site vs available), and must a physician/NP/PA perform a prior good-faith exam?

The Delaware Board of Nursing's website was checked on 2026-09-23 for a position statement, advisory opinion or FAQ on cosmetic injectables (neuromodulators, fillers) and none was found. RN practice therefore falls under the state's general nurse practice act, which was not reviewed for this entry.

The Board of Nursing page links only a general scope-of-practice decision tree.

What does the state require for elective IV hydration/vitamin (incl. NAD+) therapy: who may start IVs, is a patient-specific order or good-faith exam required before a patient's first IV, are standing orders allowed, and are there rules for mobile IV services?

The Delaware Board of Nursing's website was checked on 2026-09-23 for guidance on IV hydration clinics (prior exams, standing orders, mobile services) and none was found.

Does the state enforce the corporate practice of medicine doctrine (non-physicians may not own medical practices or employ physicians), and how does that affect med spa ownership?

Permit Health's 2025 guide lists Delaware as permitted, citing Del. Code Ann. tit. 24 §§1701 et seq.; MedPath Compliance (reviewed 2026-06-20) also lists Delaware as 'No'.

Who may perform laser/IPL/RF aesthetic procedures (laser hair removal, resurfacing): physicians only, delegated to RNs/PAs, or licensed electrologists/estheticians/laser technicians with state certification?

No Delaware statute, rule or board policy on delegation of cosmetic laser/IPL procedures or a laser-operator credential was located on 2026-09-23.

Does the state license clinical laboratories itself, beyond federal CLIA certification, including out-of-state labs that test specimens from the state?

Most states rely on federal CLIA certification alone. The states confirmed in this research as issuing their own lab licenses are California, New York, Pennsylvania, Maryland and Rhode Island (which also reach out-of-state labs testing specimens from their residents), plus Nevada, Washington, Massachusetts, New Jersey and New Hampshire (labs located in the state). Delaware was not among them, but this research did not confirm its statutes. Delaware's CLIA state agency is Delaware State Public Health Laboratory (CLIA.delaware@delaware.gov, 302-802-5000); it can confirm whether any state license or permit applies, including to out-of-state labs.

Absence of a state license was not verified against the state's statutes or rules.

May consumers order their own lab tests without a practitioner order (direct access testing)? A practitioner-ordered panel is always fine; this matters for take-home and consumer test kits.

ADLM (formerly AACC) reported in 2019 that 37 states and DC let consumers order some or all tests directly, but it did not publish the state list, and this research did not confirm Delaware's rule. Delaware's lab regulator (CLIA state agency) is Delaware State Public Health Laboratory (CLIA.delaware@delaware.gov, 302-802-5000). The question matters for take-home and consumer test kits, not for panels a clinician orders.

The ADLM figure dates from 2019 (older than 2 years).

Has the state enacted a law or rule specifically about stem cell, exosome or regenerative-medicine therapies (notice/disclosure duties, permission for certain non-FDA-approved uses, or Right to Try extensions covering them)?

Compilations of state stem-cell laws from 2024 to 2026 list about a dozen states with specific laws (California, Florida, Georgia, Mississippi, Nevada, North Carolina, Tennessee, Texas, Utah, Vermont, Washington and Wyoming), plus Montana's general experimental-treatment law and Kansas's state stem cell center. Delaware is not among them. Without a state-specific law, regenerative products are governed by federal FDA rules plus the state's general medical practice, advertising and consumer-protection laws, enforced by its medical board. Federal FDA rules still apply regardless of state law: stem cell, birth-tissue and exosome products are regulated by FDA, and a state law cannot make an unapproved biologic FDA-approved.

The finding of no law rests on multi-state compilations (a commercial one from Aug 2026 and a peer-reviewed one from Feb 2024, which is older than 2 years) and targeted searches, not a statute-by-statute review, and neither compilation is exhaustive. General Right to Try laws for terminal patients, where they exist, were not reviewed here.

Does the state have cosmetic or sunscreen requirements beyond federal MoCRA, such as ingredient bans (PFAS, formaldehyde, phthalates), ingredient reporting, sunscreen-ingredient bans, or bans on selling animal-tested cosmetics?

Delaware does not appear on 2026 compilations of state PFAS-in-cosmetics laws, on the list of states banning animal-tested cosmetics, or among the jurisdictions with sunscreen-ingredient bans. Federal MoCRA and FDA rules on cosmetics and OTC sunscreens still apply. Other state laws that touch cosmetics generally, such as state food-drug-cosmetic acts or consumer-protection laws, were not surveyed.

The animal-testing list is Wikipedia's 'as of 2023' compilation (older than 2 years); effective dates were not confirmed.